Echocardiographic response and predictors of reverse remodeling after sacubitril/valsartan in de novo heart failure with reduced ejection fraction: cohort study
- 1Division of Cardiology, Department of Internal Medicine, Uijeongbu Eulji Medical Center, Eulji University College of Medicine, Uijeongbu, Republic of Korea
Abstract
Background: Sacubitril/valsartan (angiotensin receptor-neprilysin inhibitor, ARNI) improves outcomes in heart failure with reduced ejection fraction (HFrEF), yet treatment response varies and predictors of response remain incompletely defined. We aimed to evaluate real-world echocardiographic responses to ARNI and identify predictors of favorable response in patients with newly diagnosed HFrEF.
Methods: Consecutive patients who initiated ARNI at Uijeongbu Eulji University Hospital between March 2021 and August 2024 were prospectively enrolled. Echocardiographic reverse remodeling was assessed by changes in left ventricular (LV) ejection fraction (EF). Based on the degree of echocardiographic response, patients were categorized as nonresponders [follow-up left ventricular ejection fraction (LVEF) <40% and an absolute increased in LVEF <10%], partial responders (follow-up LVEF ≥40% and <50%, or an absolute increase in LVEF ≥10% with follow-up LVEF <50%), or super responders (follow-up LVEF ≥50%). Clinical outcomes were assessed using Kaplan-Meier analysis, and predictors of response were evaluated using multivariable logistic regression.
Results: Among 392 patients who completed follow-up echocardiography (median follow-up interval, 11.0 months), 116 (29.6%) were nonresponders, 110 (28.0%) were partial responders, and 166 (42.3%) were super responders with a recovery of LVEF ≥50%. During a median follow-up of 708 days, nonresponders experienced significantly higher rates of clinical events, including death or heart failure rehospitalization, compared with responders (P<0.001). In multivariable analysis, higher baseline systolic blood pressure [SBP; odds ratio (OR), 1.249; 95% confidence interval (CI): 1.120–1.400] and smaller LV end-diastolic volume (OR 0.919; 95% CI: 0.869–0.970) were independently associated with favorable echocardiographic response. Although a substantial proportion of patients did not achieve ARNI doses ≥200 mg/day, exploratory analysis did not demonstrate a significant association between ARNI dose and echocardiographic response or clinical outcomes.
Conclusions: In this real-world cohort study, ARNI therapy was associated with substantial reverse remodeling and improved clinical outcomes despite low rates of target-dose attainment. Baseline SBP and LV remodeling parameters were associated with treatment response, supporting individualized ARNI titration strategies in clinical practice.
Related
- Clinical outcomes of sacubitril/valsartan in patients with mildly reduced or preserved ejection fraction and acute heart failure: a multi-institutional study
- Mechanisms and clinical outcomes of sacubitril-valsartan and SGLT2 inhibitors in heart failure patients: a retrospective cohort study
- Real-World Sacubitril/Valsartan Adoption and Post-Initiation Dose Reassessment and Titration in Heart Failure with Reduced Ejection Fraction: An Explanatory Sequential Mixed-Methods Study from Northern Saudi Arabia
- Body Mass Index, Valsartan, and Myocardial Remodeling in Early‐Stage Hypertrophic Cardiomyopathy: A Secondary Analysis of the Randomized VANISH Trial
- Automatic transesophageal echocardiographic evaluation of patients with mitral valve prolapse: comparison with patients without structural cardiac chamber remodeling (an exploratory study)
BibTeX
@article{moon2026echocardiographic,
title = {{Echocardiographic response and predictors of reverse remodeling after sacubitril/valsartan in de novo heart failure with reduced ejection fraction: cohort study}},
author = {In Tae Moon and Sung Hun Park and Jung Yeon Chin},
journal = {Cardiovascular Diagnosis and Therapy},
year = {2026},
month = sep,
doi = {10.21037/cdt-2026-0233},
url = {https://doi.org/10.21037/cdt-2026-0233},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Echocardiographic response and predictors of reverse remodeling after sacubitril/valsartan in de novo heart failure with reduced ejection fraction: cohort study
AU - In Tae Moon
AU - Sung Hun Park
AU - Jung Yeon Chin
PY - 2026
DA - 2026/09/28
JO - Cardiovascular Diagnosis and Therapy
DO - 10.21037/cdt-2026-0233
UR - https://doi.org/10.21037/cdt-2026-0233
AB - Background: Sacubitril/valsartan (angiotensin receptor-neprilysin inhibitor, ARNI) improves outcomes in heart failure with reduced ejection fraction (HFrEF), yet treatment response varies and predictors of response remain incompletely defined. We aimed to evaluate real-world echocardiographic responses to ARNI and identify predictors of favorable response in patients with newly diagnosed HFrEF. Methods: Consecutive patients who initiated ARNI at Uijeongbu Eulji University Hospital between March 2021 and August 2024 were prospectively enrolled. Echocardiographic reverse remodeling was assessed by changes in left ventricular (LV) ejection fraction (EF). Based on the degree of echocardiographic response, patients were categorized as nonresponders [follow-up left ventricular ejection fraction (LVEF) <40% and an absolute increased in LVEF <10%], partial responders (follow-up LVEF ≥40% and <50%, or an absolute increase in LVEF ≥10% with follow-up LVEF <50%), or super responders (follow-up LVEF ≥50%). Clinical outcomes were assessed using Kaplan-Meier analysis, and predictors of response were evaluated using multivariable logistic regression. Results: Among 392 patients who completed follow-up echocardiography (median follow-up interval, 11.0 months), 116 (29.6%) were nonresponders, 110 (28.0%) were partial responders, and 166 (42.3%) were super responders with a recovery of LVEF ≥50%. During a median follow-up of 708 days, nonresponders experienced significantly higher rates of clinical events, including death or heart failure rehospitalization, compared with responders (P<0.001). In multivariable analysis, higher baseline systolic blood pressure [SBP; odds ratio (OR), 1.249; 95% confidence interval (CI): 1.120–1.400] and smaller LV end-diastolic volume (OR 0.919; 95% CI: 0.869–0.970) were independently associated with favorable echocardiographic response. Although a substantial proportion of patients did not achieve ARNI doses ≥200 mg/day, exploratory analysis did not demonstrate a significant association between ARNI dose and echocardiographic response or clinical outcomes. Conclusions: In this real-world cohort study, ARNI therapy was associated with substantial reverse remodeling and improved clinical outcomes despite low rates of target-dose attainment. Baseline SBP and LV remodeling parameters were associated with treatment response, supporting individualized ARNI titration strategies in clinical practice.
SN - 2223-3652
SN - 2223-3660
ER -